| Number: CTEP 8762 |
Principal Investigator: Ma, Cynthia |
| Title: A Phase 1 Trial of MK-2206 in Combination with Anastrozole, Fulvestrant, or Anastrozole plus Fulvestrant in Postmenopausal Women with Estrogen Receptor Positive Metastatic Breast Cancer |
| Description: The purpose of this research study is to find out what effects, good and/or bad, the drug MK-2206 has on you and your metastatic breast cancer when given in combination with hormonal therapy (anastrozole or letrozole), which blocks or limits the production of estrogen, which estrogen receptor-positi...MORE |
| ___________________________________________________________________________________________________ |
| Number: COG ADVL1011 |
Principal Investigator: Hayashi, Robert |
| Title: A Phase I Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms |
| ___________________________________________________________________________________________________ |
| Number: 201303150 |
Principal Investigator: Tan, Benjamin |
| Title: A phase I/II study of X-82, an oral anti-VEGFR tyrosine kinase inhibitor, with everolimus for patients with pancreatic neuroendocrine tumors |
| Description: The purpose of this research study is to determine the best dose of a drug called X-82 when it is combined with everolimus, as well as to look at side effects that may occur when people receive this combination of drugs....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201202074 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects with Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287 |
| Description: The purpose of this research study is to discover more information about a drug called U3-1287. Early research about this drug has shown that in order for this drug to be most effective, a certain concentration of the drug must be reached in the body. During the course of this study, we are planning...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210037 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I safety study of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies |
| Description: The purpose of this research study is to learn whether the use of Clostridium-novyi-NT in people with your type of cancer is safe and effective. Clostridium novyi-NT spores are bacteria. In laboratory animals, Clostridium novyi-NT spores can grow within tumors and destroy a large part of the tumors....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201204116 |
Principal Investigator: Lockhart, A. Craig |
| Title: An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers |
| Description: The purpose of this research study is to learn whether a drug called vemurafenib is safe and effective in cancers caused by problems with the BRAF gene. Previous studies have shown that vemurafenib therapy can be beneficial in patients with a special type of metastatic melanoma that is caused by pro...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201201055 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects with Cancer Who Also Have Impaired Renal Function |
| Description: The purposes of this research study are to determine the effect of kidney damage on the amount of E7389 in your blood and how quickly
the body gets rid of it, to explore how safe E7389 is for subjects with kidney damage, or to see if E7389 causes any decrease in the size of your cancer. Eribulin me...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201112113 |
Principal Investigator: Lockhart, A. Craig |
| Title: An open-label, multi-center Phase I dose-finding study of RAD001 (everolimus, Afinitor®) in combination with BEZ235 in patients with advanced solid tumors |
| Description: The purpose of this research study is to find out if the drugs RAD001 (Everolimus, Afinitor®) and BEZ235 given in combination are safe and have beneficial effects in people who have advanced solid tumors. This study has two parts. In the dose-finding part of the study, you will be assessed to find t...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104365 |
Principal Investigator: Lockhart, A. Craig |
| Title: An open label, non-randomized Phase I study of regorafenib (BAY 73-4506) to evaluate cardiovascular safety, tolerability, pharmacokinetics, and anti-tumor activity in patients with advanced solid tumors |
| Description: The purpose of this study is to find the answers to the following research questions:
1. Are there any side effects to your heart when taking the study drug (BAY 73-4506) that have not yet been seen in other studies using BAY 73-4506?
2. What are the other side effects of BAY 73-4506 when you take...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201104354 |
Principal Investigator: Govindan, Ramaswamy |
| Title: A Phase 1 study of BAY 80-6946 (phosphatidylinositol 3 - kinase inhibitor) in combination with paclitaxel in subjects with advanced solid malignancy |
| Description: The purpose of this study is to find the highest and safest dose of an investigational drug called BAY 80-6946 in
combination with paclitaxel, determine the side effects of a weekly dosing, determine how much BAY 80-6946 is in the blood at specific times after administration, determine if this comb...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |